Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors.

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

Calidi Biotherapeutics, Inc., a clinical-stage biotech company, announced it has entered a definitive agreement to immediately exercise existing warrants to purchase up to 6,595,000 shares of its ...

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company's precision genetic medicine ...

SAN DIEGO - Calidi Biotherapeutics, Inc. (NYSE American:CLDI), currently trading at $1.09 per share with a market capitalization of $11.25 million, announced Wednesday it has entered into a ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease.